salmeterol xinafoate has been researched along with Arrhythmia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumgartner, RA; Cheng, H; Grogan, DR; Hanrahan, JP; Morganroth, J; Wilson, A; Zimetbaum, PJ | 1 |
| Baumgartner, RA; Donohue, JF; Goodwin, E; Grogan, DR; Hanania, NA; Hanrahan, JP; Sciarappa, KA | 1 |
| Martínez, MA; Perpiñá, M; Román, P; Sánchez, L; Soler, JJ | 1 |
| Calderaro, F; Cazzola, M; Di Perna, F; Imperatore, A; Imperatore, F; Matera, MG; Salzillo, A | 1 |
| Calderaro, F; Califano, C; Cazzola, M; Di Pema, F; Donner, CF; Matera, MG; Vinciguerra, A | 1 |
| Chervinsky, P; Gross, G; Pearlman, DS; Prillaman, B; Shah, T; Stricker, W; Weinstein, S; Woodring, A | 1 |
5 trial(s) available for salmeterol xinafoate and Arrhythmia
| Article | Year |
|---|---|
Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Aged; Albuterol; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Ethanolamines; Female; Formoterol Fumarate; Heart Rate; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Tachycardia; Treatment Outcome | 2008 |
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Topics: Albuterol; Arrhythmias, Cardiac; Bronchitis; Bronchodilator Agents; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Ipratropium; Male; Middle Aged; Myocardial Ischemia; Nebulizers and Vaporizers; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Salmeterol Xinafoate; Tremor | 2008 |
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Arrhythmias, Cardiac; Cross-Over Studies; Electrocardiography, Ambulatory; Ethanolamines; Female; Formoterol Fumarate; Heart; Heart Rate; Humans; Hypoxia; Lung Diseases, Obstructive; Male; Middle Aged; Potassium; Respiratory Function Tests; Safety; Salmeterol Xinafoate; Single-Blind Method | 1998 |
Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Albuterol; Arrhythmias, Cardiac; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Forced Expiratory Flow Rates; Forced Expiratory Volume; Heart Rate; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Salmeterol Xinafoate; Terbutaline; Time Factors; Tremor | 1999 |
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Arrhythmias, Cardiac; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Pilot Projects; Safety; Salmeterol Xinafoate; Severity of Illness Index; Treatment Outcome | 1999 |
1 other study(ies) available for salmeterol xinafoate and Arrhythmia
| Article | Year |
|---|---|
Risk factors of emergency care and admissions in COPD patients with high consumption of health resources.
Topics: Administration, Inhalation; Aged; Albuterol; Arrhythmias, Cardiac; Bronchodilator Agents; Case-Control Studies; Emergency Treatment; Forced Expiratory Volume; Health Resources; Hospitalization; Humans; Male; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Regression Analysis; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires; Vital Capacity | 2004 |